HT 0712

Drug Profile

HT 0712

Alternative Names: HT-0712; IPL-455903

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Developer Dart NeuroScience
  • Class Anti-inflammatories; Cyclopentanes; Nootropics; Phenyl ethers; Piperidones; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Memory disorders

Most Recent Events

  • 29 Jul 2015 Phase-II development is ongoing in USA and Europe
  • 01 Jan 2015 Dart NeuroScience completes a phase II trial in Memory disorders in USA (NCT02013310)
  • 01 Dec 2013 Phase-II clinical trials in Memory disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top